ICICI Direct's research report on Aarti Industries
Aarti Industries’ Q3FY21 revenues grew 9.5% YoY to Rs 1186.8 crore, mainly due to 31.8% growth in pharma segment to Rs 232.2 crore. Speciality chemical revenues grew 3.5% YoY to Rs 1078.8 crore, lower than I-direct estimates of Rs 1162.7 crore. EBITDA margins improved 55 bps YoY, 233 bps QoQ to 24%. Improvement in gross margins by 303 bps YoY, 339 bps QoQ was partially offset by increase in other expenditure. EBITDA grew 12.1% YoY to Rs 285 crore. PAT grew 18.2% YoY to Rs 165.3 crore. Delta vis-à-vis EBITDA was mainly due to lower interest cost.
Outlook
We maintain BUY with a TP of Rs 1340 (22x of FY23E EPS of Rs 56.1) vs. earlier target price of Rs 1235.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!